#Vienna #Austria #Medical Cyclotron #Longevous Beamtech #LB-30

Longevous Beamtech Unveils LB-30 at EANM 2026

Vienna, October 20, 2026 — At the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026), Longevous Beamtech (LBT) showcased its newest medical cyclotron platform, the LB-30 series, designed to operate at energy levels of 30 MeV. This groundbreaking platform marks a significant advancement in the field of radionuclide production and radiopharmaceutical research.

Expanding Radionuclide Production

As the landscape of radiopharmaceutical development evolves, the demands for radionuclide production have grown increasingly complex. Beyond the established PET isotopes commonly used in clinical routines, research institutions and radiopharmaceutical companies are exploring a wider variety of radionuclides for diagnostic, therapeutic, and research applications. The LB-30 platform has been meticulously engineered to address these changing production requirements, showcasing features such as multi-particle compatibility, continuously variable beam energy extraction, high-efficiency beam transport, re-evacuation technology, and flexible target station solutions. This enables enhanced flexibility in selecting particle types, beam energies, and target configurations to meet diverse irradiation needs, thus supporting a broader array of radionuclide production pathways and research applications.

Furthermore, the LB-30 represents a further step in the expansion of LBT’s cyclotron portfolio. While existing systems are geared towards routine clinical isotope production and multi-isotope applications, the new platform is designed to enhance opportunities for higher energy production, the development of innovative isotopes, and advanced research capabilities.

Comprehensive Production Solutions

Alongside the launch of the LB-30, LBT has consistently developed its expertise throughout the radionuclide and radiopharmaceutical production workflow. Their product portfolio includes target systems, solutions for radiopharmaceutical synthesis and dosimetry, hot cells, quality control solutions, engineering, installation, training, and lifecycle support. This integrated approach allows production facilities to be tailored to specific isotope requirements, production volumes, research goals, and future development plans, catering effectively to hospitals, radiopharmaceutical manufacturers, and research institutions.

LB-30's Debut at EANM 2026

During EANM 2026, LBT presented the LB-30 to nuclear medicine professionals, radiopharmaceutical companies, researchers, and industry partners from various international markets. Discussions throughout the congress revolved around radionuclide production, radiopharmaceutical development, and the changing technical requirements for future production facilities. This provided LBT with an invaluable opportunity to engage directly with experts from across the nuclear medicine community.

With its unveiling at the congress, the LB-30 stands as the latest addition to LBT's medical cyclotron portfolio, enhancing the company's capabilities in the production of high-energy, versatile radionuclides and fostering advancements in the radiopharmaceutical research domain. As the demand for innovative radiopharmaceuticals grows, the LB-30 is poised to play a crucial role in shaping the future of nuclear medicine.

Contact: [email protected]